MediciNova Inc. - MNOV EV/EBITDA Multiple

Corporate emblem and logo of MediciNova Corp (MNOV)

MediciNova, Inc. (MNOV) is scaling long-term tests of its molecule portfolio, aiming for Phase II/III success and partnerships with industry behemoths. The company is developing MN-166, a unique anti-inflammatory agent for the therapy of ALS and multiple sclerosis. The price indicator on the chart shows a value of 0.00, which is critical for a business whose future profitability relies on a patent monopoly in the treatment of severe neurodegenerative pathologies.

MNOV (MediciNova Inc.) EV/EBITDA Multiple history from 11/23/2025 to 11/14/2026

MNOV (medicinova.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart MediciNova|MNOV - Broker Consensus Forecast
- issuer market value details:
Market Capitalization MediciNova, Inc.|MNOV - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share MediciNova|MNOV - Book Capitalization|Market Value to Book Value Ratio medicinova.com|MNOV - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity MediciNova, Inc.|MNOV - Long-Term Liabilities to Capital|Short-Term Debt to Equity MediciNova|MNOV - Company Debts|Debt to Book Capitalization Ratio MediciNova, Inc.|MNOV - Long-Term Debt|Company Short-Term Debts MediciNova|Quick Liquidity Indicator medicinova.com
- net income and valuation multiples indicators:
MNOV - Company Net Income|Expected Profit MediciNova, Inc.|MNOV - Price to Earnings Ratio|Forward P/E Multiple MediciNova|MNOV - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple MediciNova, Inc.|MNOV - Operating profit before amortization|Net earnings per share (EPS TTM) MediciNova|MNOV - Net earnings per share for the last four quarters|Quarterly EPS earnings growth medicinova.com|MNOV - Net earnings per share growth this year|Earnings growth forecast for next year MediciNova, Inc.
- total revenue and sales volume data:
MNOV - Company Gross Revenue|Company Projected Revenue MediciNova|MNOV - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio MediciNova, Inc.
Summary company analytics:MNOV (MediciNova Corp)
Original product of MediciNova

The enterprise value to EBITDA ratio allows for an assessment of MediciNova, Inc. (MNOV) resilience to market shocks, given the capital intensity of R&D and the patent protection of its drugs. By analyzing the company's EV/EBITDA chart, an investor can see the ratio of the total asset value, including debt, to its actual earnings, which helps identify position accumulation phases or overvaluation risks under strict FDA oversight.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc. (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Therapeutics CTNM|Larimar Therapeutics Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CAPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entrada Therapeutics, Inc|PTHS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple serinatherapeutics.com SER|Enterprise Value to EBITDA Ratio BTAI|Company Value to EBITDA ProMIS PMN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apimeds Pharmaceuticals (APUS)|Enterprise Value to EBITDA Ratio aeonbiopharma.com AEON|EV/EBITDA Multiple NLSP (NLS Pharmaceutics)|Bionomics Ltd. (BNOX) - Company Value to EBITDA|FSD Pharma Inc. - EV/EBITDA Multiple|RETA (Reata Pharmaceuticals Inc) - Enterprise Value to Operating Income Before Depreciation